利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

170 条记录 (耗时 0.054 秒)

    Antisense oligonucleotide modulation of raf gene expression
    141.
    发明授权
    Antisense oligonucleotide modulation of raf gene expression 失效
    raf基因表达的反义寡核苷酸调控

    公开(公告)号：US06806258B2

    公开(公告)日：2004-10-19

    申请号：US10057550

    申请日：2002-01-25

    申请人： Brett P. Monia

    发明人： Brett P. Monia

    IPC分类号： C07H2100

    CPC分类号： C12N15/1135 ,  A61K38/00 ,  C12N15/1137 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3517 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3527

    摘要： Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating or preventing conditions, including hyperproliferative conditions, associated with raf expression.

    摘要翻译： 提供寡核苷酸，其靶向编码人raf的核酸并能够抑制raf表达。 寡核苷酸可以在一个或多个位置具有化学修饰，并且可以是嵌合寡核苷酸。 还提供了使用本发明的寡核苷酸抑制人raf表达的方法。 本发明还包括抑制细胞过度增殖的方法以及治疗或预防与raf表达相关的病症（包括过度增殖病症）的方法。

    Methods for modulating factor 12 expression
    145.
    发明授权
    Methods for modulating factor 12 expression 有权
    调节因子12表达的方法

    公开(公告)号：US09150864B2

    公开(公告)日：2015-10-06

    申请号：US13884067

    申请日：2011-11-08

    申请人： Brett P. Monia ,  Robert A. MacLeod ,  Jeffrey R. Crosby

    发明人： Brett P. Monia ,  Robert A. MacLeod ,  Jeffrey R. Crosby

    IPC分类号： C07H21/04 ,  C12N15/113

    CPC分类号： C12N15/1137 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/321 ,  C12N2310/3525

    摘要： Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

    摘要翻译： 本文公开了减少因子12并治疗或预防有此需要的个体血栓栓塞症状的方法。 通过施用靶向因子12的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞，中风和肠系膜血栓形成。 抑制因子12的方法也可用作预防性治疗以预防患有血栓栓塞和栓塞危险的个体。

    Antisense inhibition of E2A-Pbx1 expression
    148.
    发明授权
    Antisense inhibition of E2A-Pbx1 expression 有权
    E2A-Pbx1表达的反义抑制

    公开(公告)号：US06607915B1

    公开(公告)日：2003-08-19

    申请号：US09624945

    申请日：2000-07-25

    申请人： Brett P. Monia ,  Edward Wancewicz

    发明人： Brett P. Monia ,  Edward Wancewicz

    IPC分类号： C07H2104

    CPC分类号： C12N15/1135 ,  A61K38/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  Y02P20/582 ,  C12N2310/3525

    摘要： Compounds, compositions and methods are provided for inhibiting E2A-Pbx1 mediated transformation. The compositions comprise antisense compounds targeted to nucleic acids encoding E2A-Pbx1. Methods of using these antisense compounds for inhibition of E2A-Pbx1 expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of E2A-Pbx1 are provided.

    摘要翻译： 提供化合物，组合物和方法用于抑制E2A-Pbx1介导的转化。 组合物包含靶向编码E2A-Pbx1的核酸的反义化合物。 提供了使用这些反义化合物抑制E2A-Pbx1表达和治疗与E2A-Pbx1的过度表达或组成型激活相关的疾病，特别是癌症的方法。